The susceptibilities of varicella-zoster virus (VZV) and herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) to 17 nucleoside analogs were compared by a plaque reduction assay with human embryonic lung fibroblast cells. The susceptibility of VZV to certain nucleoside analogs was different from that of HSV-1. Against VZV the 5-halogenovinyl-arabinosyluracils were the most potent of the compounds tested.
arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU), 1-P-D-arabinofuranosyl-E-5-(2-chlorovinyl)uracil (CV-araU), 1- ,-D-arabinofuranosyl-E-5-(2-iodovinyl)uracil (IV-araU), and 1-p-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil-5' -monophosphate (BV-araUMP) (7, 8) ; 1-p-D-arabinofuranosyl- 5 -vinyluracil (vinyl-araU), 5-hydroxy-2 '-deoxyuridine (OH-dUrd), 5-methoxycarbonylmethyl-2'-deoxyuridine (MCM-dUrd), and 5-acetonyl-2'-deoxyuridine (aceto-dUrd) (12) ; arabinofuranosylthymine (araT) and 5-iodo-2'-deoxyuridine (1-dUrd) ( Although all of the nucleoside analogs tested (Table 1) were active against the various strains of HSV-1, including the clinical isolates, the 5-halogenovinyl-arabinosyluracils (XV-araUs), BVDU, the 2'-fluoro-arabinosylpyrimidine nucleosides (F-araPyr), and acyclovir were especially active. OH-dUrd, araT, FIAC, FMAU, and acyclovir were almost as active against HSV-2 as against HSV-1. In contrast, HSV-2 was much less susceptible to BVDU, vinyl-araU, XV-araUs, BV-araUMP, ethyl-araU, and aceto-dUrd than was HSV-1. The 50% plaque reduction doses of the latter compounds for HSV-2 were generally two or more orders of magnitude greater than those for HSV-1. HSV-2 strains were, on the average, 10 to 30 times less susceptible than were HSV-1 strains to I-dUrd, MCM-dUrd, and FVAU. Although the compounds varied enormously in potency, there was little variation in the susceptibilities of strains of either HSV-1 or HSV-2, including the clinical isolates, to a particular compound. VZV was more susceptible than HSV-1 to XV-araUs and BV-araUMP and, like HSV-1, was susceptible to the other nucleoside analogs, with the exception of ethyl-araU. However, VZV was less susceptible than HSV-1 to EDU, vinyl-araU, ethyl-araU, aceto-dUrd, and acyclovir. Overall, the variation in the susceptibilities of different strains of VZV to a particular compound was relatively great. The inhibition of cell growth by XV-araUs, BV-araUMP, OH-dUrd, aceto-dUrd, and ethyl-araU was less than 50% at a drug concentration as high as 800 ,uglml. The antiviral indexes of XV-araUs and BV-araUMP for HSV-1, calculated as the ID50 for HEL-F cells divided by the 50% plaque reduction dose for HSV-1, were greater than 50,000, and those for VZV were greater than 1,900,000. These values were the highest among those of the compounds tested. BVDU, MCM-dUrd, araT, vinyl-araU, and acyclovir also had low inhibitory action on cell growth (ID5os, 100 to 650 p,g/Iml), whereas F-araPyr and I-dUrd were found to have inhibitory action. The antiviral indexes of F-araPyr for HSV were less than 1,000.
The activity of nucleoside analogs against VZV was expected since, like HSV-1 and HSV-2, VZV is capable of inducing virus-specific TK (2, 9) . Specific phosphorylation in virus-infected cells is a general phenomenon that has been observed for all selective inhibitors of HSV-1, HSV-2, and VZV. Indeed, all compounds tested in this study, except I-dUrd, have been shown to be selective (7, 12) . HSVinduced TK has broad substrate specificity and can phosphorylate many nucleoside analogs (1). If VZV-induced TK has the same substrate specificity and ability to phosphorylate monophosphate nucleotide derivatives as does HSV-1-induced TK, VZV and HSV-1 might be equally susceptible to each compound. However, we found some differences between the susceptibilities of HSV-1 and VZV to the 17 nucleoside analogs tested. (i) VZV and HSV-1 were almost equally susceptible to compounds such as F-araPyr, araT, and 5-substituted deoxyuridines, with the exception of EDU and aceto-dUrd. (ii) VZV was much more susceptible than HSV-1 to XV-araUs and BV-araUMP. (iii) VZV was markedly less susceptible than HSV-1 to the other compounds, including acyclovir, aceto-dUrd, EDU, ethyl-araU, and vinyl-araU. Furthermore, VZV was less susceptible than HSV-2 to ethyl-araU, EDU, and acyclovir, and both VZV and HSV-2 were less susceptible than HSV-1 to nucleoside analogs having an ethyl or a vinyl residue at the C-5 position of the pyrimidine base.
